Literature DB >> 34697493

HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity.

Jenell Stewart1,2, Jared M Baeten3,4,5.   

Abstract

Pre-exposure prophylaxis (PrEP) has revolutionized HIV prevention, but PrEP does not protect against other sexually transmitted infections (STIs). Rates of STIs are rising worldwide, with notably high incidences among PrEP-using men who have sex with men in high-income countries; in low-income and middle-income countries, data are sparse, but results from a limited number of studies among African women initiating and taking PrEP have shown high STI prevalence and incidence. Efforts aimed at markedly reducing HIV in populations worldwide include a major focus on increasing PrEP use, along with improving HIV testing and treatment in order to eliminate HIV transmission. Together, these efforts could augment continued expansion of the global STI epidemic, but they could alternatively create an opportunity to improve STI control, including the development of comprehensive sexual health programmes and research to develop new STI prevention strategies. The introduction of PrEP globally has been characterized by challenges and many successes, and its role as part of a range of robust strategies to reduce HIV infections is clear. Looking ahead, understanding rising rates of curable STIs and their relationship to HIV prevention, and considering the future directions for synergies in PrEP and STI prevention will be integral to improving sexual health.
© 2021. Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 34697493      PMCID: PMC9249100          DOI: 10.1038/s41585-021-00527-4

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   16.430


  113 in total

1.  Willingness to use pre-exposure prophylaxis among Black and White men who have sex with men in Atlanta, Georgia.

Authors:  Charlotte-Paige Rolle; Eli S Rosenberg; Nicole Luisi; Jeremy Grey; Travis Sanchez; Carlos Del Rio; John L Peterson; Paula M Frew; Patrick S Sullivan; Colleen F Kelley
Journal:  Int J STD AIDS       Date:  2016-10-20       Impact factor: 1.359

2.  Impact of a high school condom availability program on sexual attitudes and behaviors.

Authors:  M A Schuster; R M Bell; S H Berry; D E Kanouse
Journal:  Fam Plann Perspect       Date:  1998 Mar-Apr

3.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

4.  Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women.

Authors:  David B Hanna; Nancy A Hessol; Elizabeth T Golub; Jennifer M Cocohoba; Mardge H Cohen; Alexandra M Levine; Tracey E Wilson; Mary Young; Kathryn Anastos; Robert C Kaplan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

5.  Refocusing Research on Sexually Transmitted Infections.

Authors:  Robert W Eisinger; Emily Erbelding; Anthony S Fauci
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

6.  Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities.

Authors:  Chama Mulubwa; Bernadette Hensen; Mwelwa M Phiri; Kwame Shanaube; Albertus J Schaap; Sian Floyd; Comfort R Phiri; Chiti Bwalya; Virginia Bond; Musonda Simwinga; Lawrence Mwenge; Sarah Fidler; Richard Hayes; Alwyn Mwinga; Helen Ayles
Journal:  Lancet HIV       Date:  2018-12-21       Impact factor: 16.070

7.  2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

Authors:  L Ryom; A Cotter; R De Miguel; C Béguelin; D Podlekareva; J R Arribas; C Marzolini; Pgm Mallon; A Rauch; O Kirk; J M Molina; G Guaraldi; A Winston; S Bhagani; P Cinque; J D Kowalska; S Collins; M Battegay
Journal:  HIV Med       Date:  2020-09-03       Impact factor: 3.180

8.  Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults.

Authors:  Tanya L Kowalczyk Mullins; Corinne E Lehmann
Journal:  Curr Pediatr Rep       Date:  2018-04-12

9.  Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial.

Authors:  Leigh Peterson; Doug Taylor; Ronald Roddy; Ghiorghis Belai; Pamela Phillips; Kavita Nanda; Robert Grant; Edith Essie Kekawo Clarke; Anderson Sama Doh; Renee Ridzon; Howard S Jaffe; Willard Cates
Journal:  PLoS Clin Trials       Date:  2007-05-25

Review 10.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.

Authors:  Virginia A Fonner; Sarah L Dalglish; Caitlin E Kennedy; Rachel Baggaley; Kevin R O'Reilly; Florence M Koechlin; Michelle Rodolph; Ioannis Hodges-Mameletzis; Robert M Grant
Journal:  AIDS       Date:  2016-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.